Two pancreatic-enzyme products approved

Two pancreatic-Enzyme products approved

(HealthDay) -- Two drugs that supplement the digestion-aiding actions of pancreatic enzymes have been approved by the U.S. Food and Drug Administration, the agency said Thursday in a news release.

Ultresa (pancrelipase) was approved for adults and children with and other disorders that affect food digestion because the pancreas does not produce enough enzymes, the FDA said.

The second drug, Viokace (pancrelipase), is to be used in combination with a to treat adults with pancreatitis. This drug's safety and effectiveness have not been established in children, the agency said.

About 200,000 people in the United States have "pancreatic insufficiency" disorders, according to the FDA. The two new medications are the fourth and fifth to be approved for these conditions.

Both new drugs are produced by Aptalis Pharma US, based in Bridgewater, N.J.

More information: Medline Plus has more about pancreatic diseases.

add to favorites email to friend print save as pdf

Related Stories

FDA approves skin cancer drug

Oct 13, 2006

The U.S. Food and Drug Administration approved a new drug to treat a rare, slow-growing skin cancer.

FDA OKs 50th & 51st anti-retroviral drugs

Aug 14, 2007

The U.S. Food and Drug Administration has tentatively approved nevirapine tablets and a pediatric medication used to treat the human immunodeficiency virus.

Recommended for you

FDA to start regulating lab-developed tests

3 hours ago

(AP)—The Food and Drug Administration announced Thursday it will begin regulating laboratory-developed tests, a growing class of medical diagnostics that have never before been subject to federal oversight.

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

User comments